contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


abliva-ab-interim-report-january-march-2023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Abliva

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354First Quarter Summary Important events January — March 2023Abliva appointed Dag Nesse as Vice President of Clinical...

<div class="mfn-preamble">Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354</div><div class="mfn-body">First Quarter Summary Important events January — March 2023<ul><li>Abliva appointed Dag Nesse as Vice President of Clinical Operations. Mr. Nesse has joined the company’s management team.</li><li>The U.S. Patent and Trademark Office granted a composition of matter patent for the NV354 compound.</li><li>An Extraordinary General Meeting was held on March 8.</li></ul>Important events after the reporting period<ul><li>Abliva’s drug candidate NV354 was granted Orphan Drug Designation (ODD) in the U.S. for the treatment of mitochondrial disease.</li><li>Abliva’s Annual General Meeting was held on May 5. All proposals were passed by the general meeting. For more information, see <a rel="noopener" href="https://abliva.com/news/resolutions-from-annual-general-meeting-in-abliva-ab-publ-on-may-5-2023/.">https://abliva.com/news/resolutions-from-annual-general-meeting-in-abliva-ab-publ-on-may-5-2023/</a>.</li></ul>Financial informationJanuary-March 2023*<ul><li>Net revenues: SEK 0 (0)</li><li>Other operating income: SEK 1,055,000 (0)</li><li>Loss before tax: SEK 16,092,000 (22,028,000)</li><li>Loss per share before dilution: SEK 0.02 (0.05)</li><li>Diluted loss per share: SEK 0.02 (0.05)</li></ul>* APM Alternative performance measures, see definition on page 20.The complete Interim report is available for download below and through Abliva's website&nbsp;<a rel="noopener" href="http://www.abliva.com/">www.abliva.com</a>.</div><div class="mfn-footer mfn-d318f2261daa">For more information, please contact:<hr>Catharina Johansson, Deputy CEO, CFO&nbsp;&amp; VP Investor Relations +46 (0)46-275 62 21, <a rel="noopener" href="mailto:ir@abliva.com">ir@abliva.com</a>Abliva AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) <a rel="noopener" href="mailto:info@abliva.com">info@abliva.com</a>,&nbsp;<a rel="noopener" href="http://www.abliva.com">www.abliva.com</a>Subscribe to our news:&nbsp;<a rel="noopener" href="https://abliva.com/posts/news-subscription/">https://abliva.com/posts/news-subscription/</a> Follow&nbsp;us&nbsp;on LinkedIn:&nbsp;<a rel="noopener" href="https://www.linkedin.com/company/abliva">https://www.linkedin.com/company/abliva</a> Subscribe&nbsp;to&nbsp;our YouTube&nbsp;channel:&nbsp;<a rel="noopener" href="https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg">https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg</a></div><div class="mfn-footer mfn-72682e636cb1">Abliva – Delivering mitochondrial health<hr>Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/d2149cec-9ed7-42a3-8ec2-b94c38314f8f/abliva-q1-report-2023.pdf" class="mfn-primary">Abliva Q1 report 2023</a></div>